Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol. 2012 Nov; 127(2):345-50.
View in:
PubMed
subject areas
Adenocarcinoma
Adenocarcinoma
Adult
Adult
Aged
Aged
Antineoplastic Agents
Antineoplastic Agents
Biomarkers, Tumor
Biomarkers, Tumor
DNA Mutational Analysis
DNA Mutational Analysis
Drug Administration Schedule
Drug Administration Schedule
Endometrial Neoplasms
Endometrial Neoplasms
Female
Female
Genes, erbB-1
Genes, erbB-1
Genetic Markers
Genetic Markers
Humans
Humans
Immunohistochemistry
Immunohistochemistry
Middle Aged
Middle Aged
Mutation
Mutation
Neoplasm Recurrence, Local
Neoplasm Recurrence, Local
Prognosis
Prognosis
Quinazolines
Quinazolines
Survival Analysis
Survival Analysis
Treatment Outcome
Treatment Outcome
authors with profiles
Joan L Walker